Proactive Investors - Run By Investors For Investors

Imugene presents new HER-Vaxx cancer vaccine results

Results were presented at the ASCO annual meeting in Chicago, which attracts over 40,000 cancer specialists.
Results support the aim to treat HER-2 positive gastric cancer

Imugene Ltd (ASX:IMU) has received positive data from the ongoing patients in the phase Ib study of its HER-Vaxx cancer vaccine.

The study completed enrolment in 2018 and is ongoing, patients receive HER-Vaxx every three months to maintain high levels of cancer-targeting antibodies.

A phase II study was initiated in March 2019 dosing patients at the highest phase Ib dose.

The presentation given at the ASCO annual meeting in Chicago showed that by day 182 of the trial, patients dosed with the highest dose of HER-Vaxx tumours had either shrunk further or stabilised.

In one patient, their tumour has shrunk more than 70% since joining the trial.



All patients on the highest dose have received their day-266 does and these results will be presented in Barcelona on 3-6 July 2019.

Imugene’s managing director and CEO Leslie Chong said: “There is continued interest in the positive data from our phase Ib trial which supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”

READ: Imugene appoints venture capital executive to board

Last month, Imugene appointed Dr Jens Eckstein as a non-executive director to its board.

Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.

He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.

Strong pipeline of cancer vaccines in development

The company has a strong pipeline of cancer vaccines in development.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use